FDA proposes a framework for regulating generative AI medical devices
The FDA's Digital Health Center of Excellence published a discussion paper on how it might regulate medical devices that use generative AI. The paper sets out a two-axis risk framework: how independently a device acts, and how much harm a wrong output could cause. It also proposes competency-based premarket testing that combines benchmarking with clinical confirmation, and it covers postmarket monitoring, foundation models and agentic systems. Comments are due October 19, 2026, under docket FDA-2026-N-7874. The FDA has not yet authorized any generative AI device.
Why it's notable: This is the clearest signal so far of how the FDA may treat LLM-based clinical tools, including chatbots and agents. Those rules will decide which of these tools can be marketed for clinical use and what evidence vendors must show.